PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
ProQR Therapeutics N.V.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$1.31+0.00 (0.00%)
Close on Oct 19, 2026
Share price
−$1.47 (−52.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
ProQR Therapeutics N.V. saw revenue fall 15.9% to €15.91M over the twelve months to Dec 31, 2025. Free cash flow was -€53.81M.
Revenue
€15.91M
-15.9% vs. a year earlier
Operating income
-€43.45M
TTM Q4 2025
Free cash flow
-€53.81M
TTM Q4 2025
EPS, diluted
-0.40 EUR
TTM Q4 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €15.91M
- Net income
- -€42.18M
- EPS, diluted
- -0.40 EUR
- Free cash flow
- -€53.81M
- Book value per share
- 0.47 EUR
- Diluted shares
- 105M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
€15.91M-15.9% YoY
Operating income
-€43.45M
Net income
-€42.18M
EPS, diluted
-0.40 EUR
Free cash flow
-€53.81M
Reported period